Denosumab Injection

Mabwell Expands MAIWEIJIAN Approval for Cancer Bone Complications in China

SHANGHAI, China, May 20, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has approved the supplemental application...

By cGxPwire Editor
May 21, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Denosumab Injection

Mabwell Expands MAIWEIJIAN Approval for Cancer Bone Complications in China